The Competition Commission of Pakistan opens an in-depth investigation on a merger in the pharmaceutical sector regarding the market of meningococcal vaccines (Novartis / GSK)

Competition Authority, Pakistan

Previous article The Indian Competition Authority approves a merger of two global pharmaceutical companies subject to divestitures in seven markets for different formulations (Sun Pharma / Ranbaxy) Next article The UK Competition and Markets Authority refuses to apply the failing firm defence to clear a merger in phase II (Alliance / IBA)

13 Nov 2014

The Competition Commission of Pakistan opens an in-depth investigation on a merger in the pharmaceutical sector regarding the market of meningococcal vaccines (Novartis / GSK)

KEYWORDS

Reference

Competition Commission of Pakistan (Islamabad), Novartis / GlaxoSmithKline, 13 November 2014

CCP opens second phase review on the proposed acquisition of vaccines business (excluding influenza vaccines business except in china) of Novartis ag by Glaxosmithkline plc.* Islamabad,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Pakistan Competition Authority
Competition Commission of Pakistan (Islamabad)

Pakistan 11 contributions 1590 visits

Quotation

Pakistan Competition Authority, The Competition Commission of Pakistan opens an in-depth investigation on a merger in the pharmaceutical sector regarding the market of meningococcal vaccines (Novartis / GSK), 13 November 2014, e-Competitions Pharma & Mergers, Art. N° 70585

Visites 166